SAN DIEGO, August 28, 2025 — Leads & Copy — Oncolytics Biotech Inc. (Nasdaq: ONCY) will participate in two investor conferences next month, with CEO Jared Kelly meeting with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. The H.C. Wainwright conference takes place Tuesday and Wednesday, September 9 & 10, 2025, at the Lotte New York Palace Hotel, New York, NY. The Lake Street Capital Markets conference is on Thursday, September 11, 2025, at The Yale Club, New York, NY.
Company management will participate in one-on-one investor meetings at the conferences. Meeting requests can be submitted on the conference website, or by contacting an H.C. Wainwright or Lake Street Capital Markets representative, or by emailing jpatton@oncolytics.ca.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has shown promise in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is pursuing strategic partnerships to accelerate development and maximize commercial impact.
Contact:
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Source: Oncolytics Biotech Inc.
Source: Oncolytics Biotech Inc.
